NL-OMON39216
Recruiting
N/A
Search for genetic variations in neuropsychiatric disorders - GEZIN study
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Psychosis
- Sponsor
- Erasmus MC, Universitair Medisch Centrum Rotterdam
- Enrollment
- 1160
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •A. Inclusion criteria for probands
- •1\. All subjects must give signed, informed consent.
- •2\. Probands must have a DSM\-IV consensus diagnosis of primary psychotic disorder or mood disorder with psychotic features (schizophrenia, schizoaffective disorder, delusional disorder, bipolar I disorder, psychotic depression, post\-partum psychosis). A concurrent diagnosis of idiopathic seizure disorder or learning disability will not be an exclusion factor. Accordingly, subjects with mild MR (as determined clinically, FIQ\>\=55\) will be included, if their psychiatric symptoms and history can be clearly established.
- •3\. Subjects must be over 18 years of age at interview, male or female.;B. Inclusion criteria for informants
- •1\. The informant will have known the subject for at least two years, be familiar with their psychiatric history, and have at least one hour of contact per week with the proband (first\-degree family members preferred). As for the probands, informants must give signed, informed consent and be over 18 years of age at interview.
- •2\. Exclusion criteria are the same as for the probands given above.;C. Inclusion criteria for family members of probands
- •1\. First\-, second\-, or third degree biological family member of participating probands. As for the probands, family members must give signed, informed consent and be over 18 years of age at interview.
- •2\. Exclusion criteria are the same as for the probands given above.
- •3\. Family members may, but are not required, to meet criteria for a DSM\-IV consensus diagnosis of primary psychotic disorder or mood disorder with psychotic features.
Exclusion Criteria
- •1\. Unable to give informed consent to all aspects of the study.
- •2\. Unable to speak and be interviewed in Dutch or English (to ensure validity of the interviews).
- •3\. Psychosis is deemed secondary to substance use by the consensus diagnostic procedure because psychotic symptoms are limited to periods of likely intoxication or withdrawal, or there are persistent symptoms which are likely to be related to substance use (i.e., increasing paranoia after years of amphetamine use; symptoms limited to visual hallucinations after extensive hallucinogen use).
- •4\. The seizure disorder is deemed secondary to causative factors, such as medication (e.g., clozapine), head injury, psychogenic polydispsia, or alcohol withdrawal.
- •5\. Subjects with severe mental retardation (MR).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
Genomic study for brain and mental disorders and effectiveness and side effect of pharmacological treatmentMultifactorial psychiatric disorders including schizophrenia, mood disorders, neurocognitive disorders, eating disorders, anxiety disorders, sleep disorders, autism spectrum disorders, substance-related disorders, attention-deficit/hyperactivity disorder, learning disorderJPRN-UMIN000018892Department of Psychiatry, Nagoya University, Graduate School of Medicine2,200
Recruiting
N/A
Identification of genetic variations in patients with aortic type B dissectioI71.01DRKS00015943Klinik für Gefäßchirurgie und Endovaskuläre Chirurgie, Universitätsklinikum Heidelberg250
Recruiting
N/A
Genetic Analysis Study of Neurosurgical DiseasesCerebral aneurysms, cerebral arteriovenous malformations, epilepsyJPRN-UMIN000045255RIKEN Center for Brain Science450
Not Yet Recruiting
N/A
Genetic studies in patients with nonsyndromic orofacial clefts.cleft lip/palateorofacial cleft10027664NL-OMON29856niversitair Medisch Centrum Sint Radboud450
Completed
N/A
Genetic study to identify genetic variants which affect clinical severity in Thai patients with beta thalassemia hemoglobin Eclinical variation in patients with beta thalassemia Hb E diseasebeta thalassemia Hb E disease, Thailand, genetic modifierTCTR20211022001Siriraj Hospital338